# **SUMMARY OF PRODUCT CHARACTERISTICS**

### 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Poulvac TRT lyophilisate for oculonasal suspension for turkeys

# 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose contains:

#### **Active substance:**

Turkey rhinotracheitis virus, strain clone K, Live 10<sup>3.2</sup> - 10<sup>4.5</sup> \*CCID<sub>50</sub>

\*  $CCID_{50}$  = Cell Culture Infectious Dose 50%.

# **Excipients:**

Qualitative composition of excipients and other constituents	
Mannitol	
NZ Case Plus	
Gelatin	
Inositol	

Cream coloured lyophilisate.

### 3. CLINICAL INFORMATION

# 3.1 Target species

Turkeys.

# 3.2 Indications for use for each target species

For active immunisation of turkeys to reduce clinical signs associated with infection with TRT virus.

Onset of immunity: 3 weeks after vaccination. Duration of immunity: 14 weeks after vaccination.

### 3.3 Contraindications

None.

# 3.4 Special warnings

Vaccinate healthy animals only.

The use of the vaccine in turkeys older than 10 days does not induce sufficient protection due to the resistance against TRT increasing with age.

## 3.5 Special precautions for use

Special precautions for safe use in the target species:

In order to prevent risks of dissemination of the vaccine in the site, all the birds at the same site should be correctly vaccinated.

Do not vaccinate in mixed breeding farms where turkeys and other avian species, except chickens, are raised. The virus contained in the vaccine was shown to spread for approximately 10 days. This spreading appeared to be without any consequence for chickens.

There is a possibility that the virus may be disseminated to other avian species and care should be taken to avoid contact with other birds.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

If the vaccine is administered by spray, personal protective equipment consisting of safety goggles and a dust mask or a helmet with filtered air circulation should be worn.

Special precautions for the protection of the environment:

Not applicable.

# 3.6 Adverse events

Turkeys:

Rare	Nasal discharge <sup>1</sup> , Respiratory tract disorder <sup>2</sup>
(1 to 10 animals / 10,000 animals	
treated):	

<sup>&</sup>lt;sup>1</sup>Mild, may occur from day 7 to 8 post vaccination.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

Do not use in turkeys in lay.

<sup>&</sup>lt;sup>2</sup>May occur between day 10 and 21 post vaccination for 1-2 days.

## 3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

# 3.9 Administration routes and dosage

One dose per bird from one day of age for oculonasal use to be administered by spray, eye drop or nose drop.

Only disinfectant-free and/or antiseptic free materials should be used for the preparation of vaccine suspension.

## Spray:

The vaccine should be reconstituted with water of good quality at room temperature, e.g. deionised water or good quality drinking water. Treat water with milk powder if necessary but ensure there are no particles which may block the spray nozzle.

Remove the aluminium cap from the vaccine vial. To reconstitute the lyophilised vaccine, the rubber stopper should be removed whilst the vial is immersed in a clean plastic measuring jug containing 0.2 - 0.5 litre of water (as noted below for sprayer types). Half fill the vial with water, replace the stopper and shake to reconstitute any remaining lyophilised vaccine.

Pour into the jug and stir carefully to ensure even dispersal of the vaccine.

The vaccine should then be added to the sprayer.

The quantity of water depends on the method of administration:

Hand spray: 0.2 L/1,000 birds.

Knapsack spray: 0.5 L/1,000 birds, if the birds are housed on the ground.

0.25 L/1,000 birds, if the birds are housed in a battery.

Automatic spray equipment: 0.15 - 0.50 L/1,000 birds (hatchery).

If administered by spray, spray equipment, providing a droplet size of 0.12 - 0.15 mm has to be used (hand spray, knapsack spray, automatic spray equipment). The distance from the spraying head to the birds must be approximately 50 cm. Hold birds in boxes for approximately 30 - 45 minutes. Ensure the temperature of the holding area is 70 - 80  $^{\circ}$ F and draught free, to avoid chilling.

Spray application is only to be carried out in housings which can be closed properly. Turn off ventilation fans, if any, to avoid air movement.

### Eye drop/nose drop:

30-50 ml/1000 birds, 0.03-0.05 ml/eye or nostril.

Reconstitute vaccine by dissolving in deionised water for eye drop or nose drop at the rate of 30-50 ml to 1,000 doses. The deionised water should be at room temperature. Remove the aluminium cap and rubber stopper from the vaccine vial and add deionised water from 30-50 ml to half fill the vial. Replace the rubber stopper and shake so that all the vaccine material is completely dissolved. Pour the vaccine concentrate into the rest of the 30-50 ml and mix well.

Administer by dropper at the rate of one drop (0.03-0.05 ml) per bird into the eye or nostril. The use of standardised droppers is recommended. Hold the bird so that one eye is pointing upwards and allow one drop of vaccine to fall into the eye or nostril. Ensure that the nasal drop is inhaled. Birds should swallow during vaccination.

# 3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Administration of a 10-fold overdose does not result in significantly worse adverse events to those seen after administration of a single dose.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

# 3.12 Withdrawal periods

Zero days.

## 4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QI01CD01

To stimulate active immunity against TRT virus.

### 5. PHARMACEUTICAL PARTICULARS

### 5.1 Major incompatibilities

Do not mix with any other veterinary medicinal product.

### 5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 20 months. Shelf life after reconstitution according to directions: 4 hours.

### 5.3 Special precautions for storage

Store and transport refrigerated (2  $^{\circ}$ C – 8  $^{\circ}$ C).

Do not freeze.

Keep the container in the outer carton.

Protect from light.

## 5.4 Nature and composition of immediate packaging

Type I glass vials containing freeze dried pellet of 1,000, 2,000 or 5,000 doses, closed with siliconized type I rubber stopper and sealed with an aluminium cap.

# Pack sizes:

Cardboard box of 1 x 1,000 doses.

Cardboard box of 1 x 2,000 doses.

Cardboard box of 1 x 5,000 doses.

Cardboard box of 10 x 1,000 doses.

Cardboard box of 10 x 2,000 doses.

Cardboard box of 10 x 5,000 doses.

Not all pack sizes may be marketed.

# 5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater <or household waste>.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

### 6. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium S.A.

### 7. MARKETING AUTHORISATION NUMBER

Vm 60021/3053

### 8. DATE OF FIRST AUTHORISATION

05 November 1997

# 9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

April 2025

### 10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

Approved 15 August 2025

Gavin Hall